Assessing the safety of biologic agents in patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 51, Issue SUPPL.5, 2012, Pages

  Rubbert Roth, Andrea ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Abatacept; Adalimumab; Anakinra; Etanercept; Infliximab; Methotrexate; Rituximab; Tocilizumab; Tumour necrosis factor inhibitor

Indexed keywords

ABATACEPT; ADALIMUMAB; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANAPHYLAXIS; ANTIMICROBIAL ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BACKACHE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CELLULITIS; COLON PERFORATION; COLONIC DIVERTICULAR PERFORATION; COMORBIDITY; CONGESTIVE HEART FAILURE; COUGHING; DEMYELINATING DISEASE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DIZZINESS; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; GASTROENTERITIS; HEADACHE; HEART DISEASE; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNOGENICITY; INFECTION; INFECTION PREVENTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LATENT TUBERCULOSIS; LEUKOENCEPHALOPATHY; LUNG CARCINOMA; LUNG GRANULOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; MYCOSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SIDE EFFECT; SKIN CANCER; SKIN CARCINOMA; SOLID TUMOR; STROKE; THROMBOCYTOPENIA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VASCULITIS; VIRUS INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; HUMANS; NEOPLASMS; RECEPTORS, INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863871272     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes114     Document Type: Article

References (98)

1. Block SR. Hidden hazards and practical problems: comment on the 2002 update of the American College of Rheumatology Guidelines for the Management of Rheumatoid Arthritis. Arthritis Rheum 2002;46:3102-3.
2. Puolakka K, Kautiainen H, Mottonen T et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41.
3. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
4. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
5. Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20.
6. Gridley G, McLaughlin JK, Ekbom A et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
7. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108: 2957-63.
8. del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
9. Avina-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
10. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009;60:3761-5.
11. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-12.
12. Remicade® (infliximab) for IV injection [prescribing information]. Malvern, PA, USA: Centocor Ortho Biotech, Inc., 2009.
13. Delabaye I, De Keyser F. Remitract Study Group. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther 2010;12:R121.
14. Enbrel- (etanercept) for subcutaneous injection [prescribing information]. Thousand Oaks, CA, USA: Amgen Inc. and Wyeth Pharmaceuticals, 2009.
15. Humira (adalimumab) injection, solution [prescribing information]. North Chicago, IL, USA: Abbott Laboratories, 2009.
16. Cimzia- (certolizumab pegol) [prescribing information]. Smyrna, GA, USA: UCB, Inc., 2009.
17. Simponi (golimumab) [prescribing information]. Horsham, PA, USA: Centocor Ortho Biotech Inc., 2009.
18. Strangfeld A, Hierse F, Manger B et al. Increased risk of sepsis after termination of anti-TNF treatment. Ann Rheum Dis 2010;69:56 (abstract).
19. Enbrel 25 mg powder and solvent for solution for injection [summary of product characteristics]. Berkshire, UK: Wyeth Europa Ltd., 2010.
20. Humira 40 mg solution for injection [summary of product characteristics]. Berkshire, UK: Abbott Laboratories Ltd., 2010.
21. Cimzia- 200 mg solution for injection [summary of prescribing information]. Brussels, Belgium: UCB, Inc., 2009.
22. Simponi 50 mg solution for injection in pre-filled pen [summary of product characteristics]. Leiden, The Netherlands: Centocor B.V., 2009.
23. Remicade 100 mg powder for concentrate for solution for infusion [summary of product characteristics]. Leiden, The Netherlands: Centocor B.V., 2009.
24. Furst DE, Keystone EC, Fleischmann R et al. Updated consensus statement on biological agents for the treatments of rheumatic diseases, 2009. Ann Rheum Dis 2010;69:i2-29.
25. Lee JH, Slifman NR, Gershon SK et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
26. Wood KL, Hage CA, Knox KS et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003;167:1279-82.
27. Mertz LE, Blair JE. Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. Ann NY Acad Sci 2007;1111:343-57.
28. Rogan MP, Thomas K. Fatal miliary coccidioidomycosis in a patient receiving infliximab therapy: a case report. J Med Case Rep 2007;1:79.
29. Bergstrom L, Yocum DE, Ampel NM et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004; 50:1959-66.
30. Yamamoto M, Takahashi H, Wakasugi H et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol 2007; 17:72-4.
31. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010;62:3191-5.
32. Bellofiore B, Matarese A, Balato N et al. Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers. J Rheumatol Suppl 2009;83:76-7.
33. Hsia EC, Cush JJ, Matteson EL et al. A comprehensive tuberculosis screening program in patients with inflammatory arthritis treated with golimumab, a human anti-TNF antibody, in phase 3 clinical trials. Arthritis Rheum 2010;62:S396 (abstract).
34. Caramaschi P, Biasi D, Colombatti M et al. Anti-TNF alpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2006;26:209-14.
35. Gonnet-Gracia C, Barnetche T, Richez C et al. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008;26:401-7.
36. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MHA. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003;28:604-7.
37. De Bandt M, Sibilia J, Le Loet X et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51.
38. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61.
39. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
40. de Gannes GC, Ghoreishi M, Pope J et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31.
41. English PL, Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab. J Cutan Med Surg 2009;13:40-2.
42. Wollina U, Hansel G, Koch A et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9: 1-14.
43. Ramos-Casals M, Brito-Zeron P, Munoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007;86:242-51.
44. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 2005;61:329-36.
45. Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum 2005;53:618-20.
46. Wendling D, Paccou J, Flipo NM et al. New onset of uveitis under anti TNF therapy. A nationwide series. Arthritis Rheum 2010;62:S374 (abstract).
47. Porfyridis I, Kalomenidis I, Psallidas I et al. Etanercept-induced pleuropericardial lupus-like syndrome. Eur Respir J 2009;33:939-41.
48. Neradova A, Stam F, van den Berg JG, Bax WA. Etanercept-associated SLE with lupus nephritis. Lupus 2009;18:667-8.
49. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol 2005;11:47-9.
50. Abunasser J, Forouhar FA, Metersky ML. Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion. Chest 2008;134:850-3.
51. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
52. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. for the ATTACH Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) Trial. Circulation 2003;107: 3133-40.
53. Mann DL, McMurray JJV, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
54. van Vollenhoven RF, Emery P, Bingham CO III et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37: 558-67.
55. Sokolove J, Strand V, Greenberg JD et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:1612-7.
56. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35: 421-4.
57. Ferri C, Ferraccioli G, Ferrari D et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35:1944-9.
58. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008;8:104-6.
59. Galeazzi M, Bellisai F, Giannitti C et al. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann NY Acad Sci 2007;1110:544-9.
60. Giannitti C, Benucci M, Caporali R et al. Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol 2009;22:543-6.
61. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010;69:1691-3.
62. Kineret 100 mg solution for injection [summary of product characteristics]. Stockholm, Sweden: Biovitrum AB, 2009.
63. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
64. Kineret® (anakinra) [prescribing information]. Thousand Oaks, CA, USA: Amgen Inc., 2001.
65. Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology 2003;42: ii29-35.
66. RoActemra 20 mg/ml concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City, UK: Roche Registration Limited, 2011.
67. Mihara M, Kasutani K, Okazaki M et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731-40.
68. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;50: 552-62.
69. Weinblatt ME, Kremer JM, Cush JJ et al. Efficacy and safety of tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: a 24-week randomized study in a United States population. In: Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professional; November 5-9, 2011; Chicago, IL.
70. Schiff MH, Kremer JM, Jahreis A et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
71. Genovese MC, Sebba A, Rubbert-Roth A et al. Long-term safety of tocilizumab in rheumatoid arthritis clinical trials. In: Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professional; November 5-9, 2011; Chicago, IL.
72. Hoshi D, Nakajima A, Inoue E et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol 2012; 22:122-7.
73. van Vollenhoven RF, Siri D, Furie R et al. Long term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and a mean treatment duration of 2.4 years. Arthritis Rheum 2009;60:1955 (abstract).
74. Kobayashi K, Okamoto Y, Inoue H et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 2009;48:1307-9.
75. Actemra- (tocilizumab) injection for intravenous infusion [prescribing information]. South San Francisco, CA, USA: Genentech, Inc., 2011.
76. van Vollenhoven RF, Nishimoto N, Yamanaka H. Experience with Mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. Ann Rheum Dis 2009;68(Suppl 3):567.
77. Genentech USA, Inc. Important safety information regarding tocilizumab (Actemra/Roactemra). http://www.gene.com/gene/products/information/ actemra/pdf/actemra-september-2010-dhcp-letter.pdf (16 November 2011, date last accessed).
78. Laudes M, Schultz O, Oberhauser F et al. Inhibition of interleukin-6 signalling improves insulin sensitivity and reduces lipoprotein (A) levels in humans. Ann Rheum Dis 2010;69:317 (abstract).
79. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.
80. Orencia- (abatacept) [prescribing information]. Princeton, NJ, USA: Bristol-Myers Squibb, 2009.
81. Alten R, Kaine JL, Keystone E et al. Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure. In: Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professional; November 5-9, 2011; Chicago, IL.
82. Alten R, Kaine J, Keystone E et al. Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA) integrated analysis of five clinical trials up to 4.5 years. Ann Rheum Dis 2011;70:617 (abstract).
83. Smitten A, Becker JC, Qi K, Kelly S, Aranda R. Evaluation of the safety profile of abatacept (ABA) by prior therapy in patients with rheumatoid arthritis (RA). Ann Rheum Dis 2010;69:541 (abstract).
84. Orencia- 250 mg powder for concentrate for solution for infusion [summary of product characteristics]. Uxbridge, UK: Bristol-Meyers Squibb Pharma EEIG, 2009.
85. Becker JC, Westhovens R, Hochberg M. The long-term safety of abatacept in the treatment of rheumatoid arthritis: integrated analyses from the abatacept clinical trial program. Ann Rheum Dis 2010;69:377 (abstract).
86. MabThera 100 mg (10 mg/ml) concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City, UK: Roche Registration Limited, 2008.
87. van Vollenhoven RF, Emery P, Bingham CO et al. Long-term safety of rituximab in rheumatoid arthritis: pooled analysis of patients in clinical trials with up to 9.5 years of treatment. In: Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professional; November 5-9, 2011; Chicago, IL.
88. Rigby W, Mease PJ, Olech E, Ashby M, Tole S. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: 48-week data from SUNDIAL. In: Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professional; November 5-9, 2011; Chicago, IL.
89. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
90. Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 2009;10:816-24.
91. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47.
92. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.
93. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60: 3225-8.
94. Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-64.
95. Rituxan® (rituximab) [prescribing information]. South San Francisco, CA, USA: Genentech, 2009.
96. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88.
97. Cornejo A, Bohnenblust M, Harris C, Abrahamian GA. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation. Cancer Chemother Pharmacol 2009;64: 857-60.
98. Ding T, Ledingham J, Luqmani R et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 2010;49:2217-19.